Quantitative analysis for the differences in vasculogenic activity and sensitivity to angiogenic stimulants between human glioma cells and normal endothelial cells.


Journal

Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 11 06 2019
revised: 19 08 2020
accepted: 24 08 2020
pubmed: 1 9 2020
medline: 26 10 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

Neovascularization is a histological feature of glioma, especially of glioblastoma (GBM), being associated with tumor invasiveness and poor prognosis. However, current anti-angiogenic therapies targeting vascular endothelial cells (ECs), has exhibited poor efficacy in some GBM cases. This may be at least partially attributed to the potential of glioblastoma cells to construct blood supply chain via vasculogenic mimicry or endothelial differentiation. This study aims to explore differences in vasculogenic activity and sensitivity to angiogenic stimulants between normal human ECs and glioma cells of different grades. We found that grade IV U87 GBM cells showed highly inducible vasculogenic activity either in the orthotopic xenograft model or under in vitro angiogenic stimulants as compared with grade II CHG5 glioma cells. The hypoxia mimetic more strongly induced in vitro vasculogenic capacity and endothelial marker expression of U87 GBM cells than the stimulation with multiple proangiogenic growth factors (vascular endothelial growth factor, basic fibroblast growth factor and epidermal growth factor). In contrast, proangiogenic effect of hypoxia on human umbilical vein endothelial cells (HUVECs) was weaker than on U87 GBM cells. In addition, it was also observed that the in vitro vasculogenic process of U87 cells started later but lasted longer than that of HUVECs. These results demonstrate that when compared with normal ECs, high-grade glioma cells basically possess weaker vasculogenic activity, but exhibit higher sensitivity and longer-lasting response to angiogenic stimulants, especially to hypoxia. This may be helpful to develop novel anti-angiogenic strategies targeting both vascular ECs and vasculogenic glioma cells.

Identifiants

pubmed: 32866544
pii: S0006-8993(20)30440-6
doi: 10.1016/j.brainres.2020.147082
pii:
doi:

Substances chimiques

Angiogenesis Inducing Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

147082

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xiao-Yan Kuang (XY)

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China; Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

Yong Ren (Y)

Department of Pathology, Central Theater Command General Hospital, Wuhan 430070, China.

Cong Chen (C)

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.

Jun Su (J)

Department of Pathology, the First Affiliated Hospital of Zunyi Medical University, Zunyi 563099, China.

Hua-Mei Li (HM)

Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

Si-Jia Liu (SJ)

Emergency Department, The First Affiliated Hospital of Zunyi Medical University, Zunyi 563099, China.

Tian-Jing Sun (TJ)

Emergency Department, The First Affiliated Hospital of Zunyi Medical University, Zunyi 563099, China.

Dong-Yun Mu (DY)

Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

Jing Lu (J)

Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

Lan Chen (L)

Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

Hang-Da Qu (HD)

Experiment Center for Science and Technology, Zunyi Medical and Pharmaceutical College, Zunyi 563006, China.

You-Hong Cui (YH)

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China.

An-Yong Yu (AY)

Emergency Department, The First Affiliated Hospital of Zunyi Medical University, Zunyi 563099, China. Electronic address: anyongyu@163.com.

Xiao-Hong Yao (XH)

Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, China. Electronic address: yxh15@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH